Abatacept (Orencia) and Medicare

The short answer

• The infusion is covered by Part B. You pay 20% of the cost. There is no yearly limit. That is roughly $8,900 a year for a mid-weight adult. A Medicare supplement policy covers that 20%. It brings your cost down to almost nothing.
• The weekly shot is covered by Part D. Your costs stop at $2,100 for the whole year in 2026, whatever the medication costs.

So on paper the shot wins by a wide margin. The problem is finding a plan that covers it.

Most drug plans do not cover the self-injection

We read the drug plan formularies CMS published for 2026. A formulary is the plan’s drug list. We counted every plan. Of 5,490 Medicare drug plans, only about 23% cover Orencia’s self-injection at all.

It is much worse among standalone drug plans. These are the plans you buy alongside Original Medicare. 5 out of 367 cover it. That is 1.4%. Almost all of the plans that do cover it are Medicare Advantage plans.

This creates an awkward situation. The cheaper route is the shot. But the coverage that makes the infusion affordable is Original Medicare plus a supplement. That setup comes with a standalone drug plan. And a standalone drug plan almost certainly will not pay for the shot. The plans that do cover the shot make you get approval before every infusion. They also limit which doctors you can see.

What to do about it: do not assume. Put “Orencia” into Medicare’s plan finder with the exact form you take. See which plans in your area list it. If none do, the infusion is your route. Then a supplement policy matters a great deal.

The two forms, side by side

Infusion figures use Medicare’s published payment rate and the 750 mg dose. That is the dose for an adult between 60 and 100 kg. Under 60 kg the dose is 500 mg. Then your 20% is closer to $6,000. Over 100 kg the dose is 1,000 mg. Then it is closer to $11,900. The first year has two extra doses. The infusion visit itself is billed separately. You pay 20% of that too.

Which is cheaper for you

• Original Medicare, no supplement, and you can find a plan covering the shot: the shot, by roughly $6,800 a year. This is the best outcome. It is also the hardest to arrange.
• Original Medicare with a supplement policy: the infusion, by roughly $1,800 a year. The supplement absorbs the 20%. You are left with about the Part B deductible. The shot would still cost you the full $2,100.
• Original Medicare, no supplement, no plan covering the shot: the infusion, at about $8,900 a year. Nothing stops that number if your weight or dose changes. This is the situation to avoid. The way to avoid it is a supplement policy.
• Medicare Advantage: the plan sets its own charges. Everything stops at the plan’s yearly limit. But read the next section. With Advantage, the price is not the problem.

Whether the shot or the infusion is right for you is a medical question. They are not the same in practice. A nurse gives the infusion and watches you. The shot is weekly and you do it yourself. If money is the only thing pushing you one way, say so at your next appointment.

No approval is needed for the infusion under Original Medicare

If you are on Original Medicare and you get abatacept as an infusion, there is no prior authorization. That means no one has to approve it before you can get it. There is nothing to submit and nothing to wait for. Nobody can require you to fail a different medication first. Original Medicare is not permitted to do either.

Medicare Advantage plans are permitted to do both. This is not theoretical. One large national insurer’s 2026 policy lists Orencia infusion as “non-preferred.” It requires members to try one of six other infused medications first. Your rheumatologist may have chosen abatacept for a specific reason. The plan can still require the other drug first.

For the shot, approval is nearly always required. 92% of the plans that cover it at all require it. Nine in ten put it on the specialty tier. That is the highest-cost group of drugs. This is not a reason to pick one drug plan over another. It is a reason to start the paperwork early. Never assume a renewal is automatic.

If you are turned down, appeal. Across Medicare Advantage in 2024, only about one denial in nine was appealed. 81% of those appeals succeeded.

There is no cheaper version yet

Some biologics now have biosimilars. A biosimilar is the same medicine made by a different company, at a lower price. Abatacept does not have one. As of August 2026 the FDA has not approved any abatacept biosimilar.

One is in the pipeline. The FDA accepted an application in February 2026. Accepted is not approved. There is no date. So unlike some other infusions, there is no cheaper version to ask your doctor about yet. That makes the coverage decisions above matter more, not less.

More things to know

• The Orencia copay card does not work if you have Medicare. Federal law prohibits it. That includes Medicare Advantage and Medigap, the supplement policy. It is not the plan being difficult.
• But the manufacturer’s foundation is a different thing. It does help Medicare patients. The Bristol Myers Squibb Patient Assistance Foundation can supply the medication free. You must meet three conditions. Your income must be below their limit. You must have spent at least 3% of your household income on prescriptions this year. And you must have applied for Extra Help and been turned down. Do that last step first. Apply for Extra Help, and keep the denial letter.
• Where you get infused changes what you pay. A hospital outpatient department adds a facility fee. That is a second bill from the hospital for the room. A doctor’s office does not add one. If your bill feels higher than it should, ask where the infusion is being billed from.
• The whole $2,100 can land in January. Medicare has a program that spreads it across twelve months instead, interest-free. But you have to sign up. It is called the Medicare Prescription Payment Plan.
• Your dose depends on your weight. If your weight crosses 60 kg or 100 kg, your dose changes. So does your 20%. This can happen mid-year.
• Extra Help. If your income is modest, it can bring Part D costs to nearly nothing. It is also the gateway to the manufacturer foundation above. It is badly underused.

Free help, from someone who is not paid a commission

Few drug plans cover the self-injection. So for this medication, sitting down with a counselor is worth real money. They can check your actual local plans. It is free. They earn nothing whichever plan you choose.

• Washington: SHIBA — insurance.wa.gov/shiba or 1-800-562-6900
• Any other state: SHIP — shiphelp.org
• Check which plans cover it where you live — medicare.gov/plan-compare
• Spread the January cost — medicare.gov/prescription-payment-plan
• Extra Help — ssa.gov/medicare/part-d-extra-help

Why isn’t my infusion covered by the $2,100 cap?

Because the $2,100 cap only applies to Part D. An infusion is paid by Part B. The cap Congress created covers drugs you pick up and take yourself. A medication a nurse or doctor gives you is paid under Part B instead. There you owe 20% of the cost every time. And there is no annual ceiling at all.

It is the same Medicare. It is often the same drug and often the same disease. The rulebook depends on who puts the medicine in you. The cap and the Part B coinsurance are two separate rules. Coinsurance is your 20%. News about one does not change the other.

A worked example. If Medicare’s approved amount for a year of your infusions is $18,000, you owe about $3,600. That is this year, next year, and every year you stay on it. The $2,100 cap does not apply to any of it.

Four things do put a ceiling on Part B costs:

• A Medicare supplement (Medigap) policy, which pays the 20% for you. This is the main one. The window to buy one closes six months after you enroll in Part B in most states.
• A Medicare Advantage plan’s yearly out-of-pocket maximum, the most you pay in a year. It applies to everything the plan covers. But it comes with prior authorization attached.
• QMB, a Medicare Savings Program that eliminates the 20% entirely. QMB and Extra Help are different programs. Extra Help applies to Part D drugs only. It does nothing for a Part B drug.
• Full Medicaid, or retiree coverage that pays after Medicare.

Related

• Medicare and your medication — look up any other medication and compare your coverage options
• Why your medication needs permission first
• Tocilizumab (Actemra) and Medicare — the same infusion-versus-shot question, with a different answer
• Rheumatoid arthritis guide
• Where you get infused changes the bill — the same infusion costs more at a hospital, and the drug bill Medicare does not cover

Where these figures come from

1. Orencia prescribing information — FDA, via DailyMed. Adult rheumatoid arthritis dosing: intravenously by weight (500 mg under 60 kg, 750 mg for 60–100 kg, 1,000 mg over 100 kg) at weeks 0, 2 and 4, then every 4 weeks; or 125 mg subcutaneously once weekly, with the intravenous loading dose optional.
2. Medicare payment limit for abatacept (HCPCS J0129): $45.859 per 10 mg — CMS Part B ASP pricing file effective July 1 – September 30, 2026. A 750 mg dose is 75 units, so $3,439 per infusion; 13 maintenance infusions is $44,713 allowed, of which your 20% is about $8,943.
3. Orencia 125 mg prefilled syringe and ClickJect wholesale acquisition cost of $1,517.65 each — Bristol Myers Squibb published pricing disclosure. Weekly dosing gives an annual list cost of about $78,900.
4. Part D annual out-of-pocket cap of $2,100 and deductible of $615 for 2026 — CMS Final CY2026 Part D Redesign Program Instructions. Cap established by the Inflation Reduction Act of 2022. The 2027 cap is $2,400.
5. Part B annual deductible of $283 and 20% coinsurance with no annual limit for 2026 — CMS, “2026 Medicare Parts A & B Premiums and Deductibles,” November 2025; Social Security Act §1833(a).
6. Formulary coverage of Orencia 125 mg: on formulary for 1,245 of 5,490 plans (22.7%), of which 92.0% require prior authorization and 90.5% place it on the specialty tier; 5 of 367 standalone prescription drug plans (1.4%) cover it — analysis of the CMS Monthly Prescription Drug Plan Formulary File, released July 29, 2026. Counted by plan, not weighted by how many people are enrolled in each.
7. Orencia subcutaneous listed as a self-administered drug and therefore excluded from Part B — Medicare Administrative Contractor self-administered drug exclusion articles, including Noridian JF (A53033, which covers Washington State), Noridian JE (A53032), Novitas (A53127), First Coast (A52571), Palmetto (A53066) and WPS (A52800).
8. Step therapy permitted for Medicare Advantage Part B drugs, and not permitted in Original Medicare — 42 CFR §422.136. The 2026 step therapy example is drawn from a national insurer’s published Part B step therapy preferred drug list, revised July 2026.
9. No prior authorization program in Original Medicare covers physician-administered drugs — CMS, Prior Authorization and Pre-Claim Review Initiatives.
10. No FDA-approved abatacept biosimilar as of August 2026 — FDA biosimilar product information, current as of August 4, 2026. One application was accepted for review in February 2026; acceptance is not approval.
11. Medicare Advantage appeal rates and outcomes for 2024 (11.5% of denials appealed, 80.7% of appeals overturned) — KFF analysis of CMS data, 2026.
12. Copay card exclusion for federal healthcare program beneficiaries — Orencia copay program terms and conditions; federal Anti-Kickback Statute, 42 U.S.C. §1320a-7b. Manufacturer foundation eligibility — Bristol Myers Squibb Patient Assistance Foundation application.
13. Medicare spending: abatacept under Part B, $930 million across 33,154 beneficiaries in 2024; Orencia under Part D, $754 million across 17,660 beneficiaries — CMS Medicare drug spending dashboards, updated June 2026.

About this page

Written and reviewed by Alison Bays, MD, MPH, board-certified rheumatologist. Figures are current for 2026 and were last checked in August 2026.

This is educational information, not advice — not medical, legal, financial or insurance advice, and not a substitute for talking to your doctor or your plan. Nothing is sold here. No insurance is sold here, no plan is recommended, and neither this page nor its author is paid by any insurance company, plan, pharmaceutical manufacturer or broker. This page is not affiliated with, endorsed by, or connected to Medicare, the Centers for Medicare & Medicaid Services, or any government agency.

Found something wrong? Please tell us.